BioNxt Solutions (BNXT.CN) Stock Price
BioNxt Solutions Price
Revenue at BioNxt Solutions has contracted by 47.1% per year over the past 4 years to 26,985.00 CAD. BioNxt Solutions's net margin stands at -19,683.2%, down from -4,885.7% several years earlier. The stock trades about 21% above its 52-week low.
BioNxt Solutions stock price
BioNxt Solutions Income Statement, Balance Sheet, Cash Flow Statement
| EBITM CAD |
|---|
| NET INCOMEM CAD |
| NET INCOME GROWTH% |
| SHARESM |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| -14.00 | -20.00 | -6.00 | -6.00 | -4.00 | -6.00 |
| -16.00 | -20.00 | -12.00 | -7.00 | -5.00 | -7.00 |
| – | 25.00 | -40.00 | -41.67 | -28.57 | 40.00 |
| 57.22 | 77.45 | 91.21 | 107.35 | 113.40 | 122.49 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales BioNxt Solutions generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue BioNxt Solutions retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare BioNxt Solutions's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares BioNxt Solutions has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against BioNxt Solutions's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
BioNxt Solutions business model & stock analysis
BioNxt Solutions Eulerpool Fair Value
BioNxt Solutions historical P/E ratio, EBIT multiple, and P/S ratio
BioNxt Solutions Executives and Management Board
7 members · avg. age 45 · 0 % women
Mr. Hugh Rogers (45)
Chief Executive Officer, Director · since 2017
189,305.00 CAD
Management
Mr. Wolfgang Probst
Chief Financial Officer, Secretary, Director · since 2018
Mr. Heinrich Jehle
Managing Director, 3a-diagnostics GmbH
Mr. Thomas Beckert
Managing Director, Vektor Pharma TF GmbH
Board of Directors
Mr. Joseph Meagher
Independent Director · since 2021
Dr. Raimar Lobenberg
Independent Director
Mr. David Waterhouse
Independent Director
Frequently asked questions about BioNxt Solutions
Converted at the current exchange rate, the BioNxt Solutions share trades at 0.21 EUR (0.34 CAD).
The BioNxt Solutions share (BNXT.CN) is listed on 4 stock exchanges, including: XETRA (BXT.DE), Frankfurt (BXT.F), München (BXT.MU).
No history available for BioNxt Solutions.
The revenue cannot currently be calculated for BioNxt Solutions.
The profit cannot currently be calculated for BioNxt Solutions.
The P/E ratio cannot be calculated for BioNxt Solutions at the moment.
The P/S cannot be calculated for BioNxt Solutions currently.
The Eulerpool Quality Score for BioNxt Solutions is 2/10.
The ISIN of BioNxt Solutions is CA0909741062. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of BioNxt Solutions is A3D1K3. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of BioNxt Solutions is BNXT.CN. The ticker symbol is used to trade BioNxt Solutions shares on the stock exchange.
BioNxt Solutions paid dividends every year for the past 0 years.
BioNxt Solutions is assigned to the 'Health' sector.
The dividends of BioNxt Solutions are distributed in CAD.
BioNxt Solutions stock
BioNxt Solutions Peer Group
BioNxt Solutions Ticker
BioNxt Solutions FIGI
All fundamentals and in-depth analysis of BioNxt Solutions
Our stock analysis for BioNxt Solutions stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioNxt Solutions. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.